The GLP-1 story is not about telehealth. It is about distribution.
Four layers, one patient experience, and an architecture FDA has seen before. Once it looks like a system distributing drugs, the FDCA stops caring how the contracts are structured.
If you have been watching the GLP-1 saga thinking FDA just went after a few telehealth companies, you are missing the story.
This is about a coordinated system distributing drugs and attempting to bypass the Federal Food, Drug, and Cosmetic Act.
Here is the simple version.
Four layers
Layer 1: the brand. High gloss. Celebrity energy. Medical weight loss delivered to your door. No manufacturing. Often no doctors in house. Just very effective marketing doing exactly what it was designed to do.
Layer 2: the clinical engine. Behind the brand sits a sophisticated operation. Multi-state prescribers. Contracted physicians. Protocol-driven care at scale. Not visible to the patient. Absolutely central to the volume.
Layer 3: the pharmacy. The accomplice. 503As. 503Bs. And in some cases structures that raise questions about whether the classification matched the operation. Compounding and dispensing. FDA knows every inch of this lane.
Layer 4: the brand again. Direct to patient. Across state lines. Same branding. Same seamless experience.
The patient sees one company. FDA sees distribution.
Vioela’s note: The two pharmacy categories are worth understanding, because the whole story turns on them. A 503A pharmacy compounds for an individual patient with a prescription, answers mainly to its state board, and is exempt from manufacturing GMP. A 503B outsourcing facility can make batches without patient-specific prescriptions, and in exchange it registers with FDA, follows GMP and is inspected by FDA. Here is the part people outside the field miss: neither is supposed to routinely make what is essentially a copy of an approved drug. The exception is a shortage. While a drug sits on FDA’s shortage list, copies are permitted. When the shortage is declared over, that permission ends, and a business model built on it ends with it.
Where it gets real
In March 2026 FDA sent warning letters to 30 telehealth companies for misleading marketing of compounded GLP-1 drugs. Some made compounded products look like approved ones. Some hid who was actually compounding them.
And the pattern FDA is looking at is not new.
But first, the money. Publicly reported 2025 revenue for the leading tirzepatide products ran to roughly $36.5 billion, somewhere near 56 percent of that manufacturer’s entire business. One major telehealth platform projected $725 million in GLP-1 revenue for the same year. The broader US market exceeded $30 billion.
Nobody was walking away from those numbers quietly. Funny how everyone became deeply passionate about patient convenience when tens of billions were on the table.
But yes, it is also about the patient
As of 31 July 2025 FDA reported 1,150 adverse events tied to compounded GLP-1 products. Not confirmed causality. Likely under-reported. But signals. Real ones.
And FDA has seen this before:
- Opioid networks. Hundreds of thousands of deaths.
- Compounding failure. More than 60 deaths and 700 infections.
- Telemarketing medicine. Mass prosecution.
- Supplements. Everyone in the chain held liable.
We have seen all of it. Just never all at once.
Marketing driving demand. Clinical enabling prescribing. Pharmacy producing. Fulfilment closing the loop. Money connecting everything.
Once it looks like a system distributing drugs, the FDCA does not care how the contracts are structured. The expectations change. The responsibilities change. And so does the enforcement.
Vioela’s note: A point of inspection practice. A 503A pharmacy is exempt from GMP, but not from the law against preparing drugs under insanitary conditions. That is the hook FDA uses when it walks into a compounding pharmacy, and it is why those inspection reports read differently from a manufacturer’s. They describe what the investigator saw, such as exposed skin in the cleanroom or visible residue in the hood, more than what the paperwork lacked. And adverse events from compounded drugs are undercounted for a structural reason: traditional compounding pharmacies are not required to report them to FDA at all.
This does not stop with GLP-1
Sitting right on the same FDCA train tracks: testosterone replacement platforms, peptide ecosystems, med spas, longevity clinics.
Different products. Same architecture, as it appears to me.
We have seen how this ends before.
Adapted from a post first published on LinkedIn. Discusses publicly reported enforcement actions and publicly reported financials.